Lymphoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Phenotypic and genotypic studies revealed that the lymphoma is originated from either NK- or γδ T-cell, both of which express CD56.
|
31041299 |
2019 |
Lymphoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
CD16/CD56 expression without CD38<sup>higher</sup> and the lack of CD16/CD56 with CD38<sup>higher</sup> expression proves to be a reliable, fast, and cost-effective method for diagnosing 11q aberration and MYC rearrangements in CD10(+) aggressive lymphomas, respectively.
|
29327714 |
2018 |
Lymphoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Described for the first time in 1994 as CD4+ cutaneous lymphoma with high expression of CD56, BPDCN has been known previously with various names such as blastic natural killer (NK) leukemia/lymphoma, agranular CD4+ CD56+ hematodermic neoplasm, and agranular CD4+ NK cell leukemia.
|
29237977 |
2018 |
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
The aim of this work was to study the expression of human leukocyte antigen G (HLA-G) and interleukin 10 (IL-10) in conjunction with expression of HLA-G killer-cell inhibitory receptor ligand immunoglobulin-like transcript 2 (ILT2) in CD3+, CD19+, CD56+ lymphomas, and ILT4 in CD14+ cells from patients with systemic lupus erythematosus (SLE).
|
22562117 |
2013 |
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
The NK-92 cell line (CD56+/CD3-) that was isolated from a patient with lymphoma has predictable high cytotoxic activity and can be expanded under good manufacturing practice conditions in recombinant interleukin-2.
|
24094496 |
2013 |
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
This nodal EBV(+) lymphoma possessed a distinctive immunophenotype of high CD8(+), CD56(-) pattern with an aggressive clinical course (median, 6.6 months).
|
22690710 |
2012 |
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
In type II EATL, lymphoma cells of the 16 (80%) and 11 (55%) cases were positive for CD56 and CD8, respectively.
|
21323966 |
2011 |
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
We recently reported that overexpression of miR-21 and/or miR-155 leads to activation of the phosphoinositide 3-kinase (PI3K)-AKT pathway in malignant lymphomas expressing CD3(-)CD56(+) natural killer (NK) cell antigen.
|
21502955 |
2011 |
Lymphoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
In the present study, we found that in NK-cell lymphoma lines (n = 10) and specimens of primary lymphoma (n = 10), levels of miR-21 and miR-155 expression were inversely related and were significantly greater than those found in normal natural killer (CD3(-)CD56(+)) cells (n = 8).
|
19641183 |
2009 |
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
CD4+/CD56+ hematodermic neoplasm (HN), formerly known as a blastic natural killer (NK) cell lymphoma, is a rare subtype of a cutaneous dendritic cell neoplasm notable for highly aggressive behavior.
|
18005171 |
2008 |
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
To investigate the clinicopathological features of six unusual cases of nodal CD56+ and Epstein-Barr virus (EBV)+ T/natural killer (NK)-cell lymphoma, a putative nodal counterpart of nasal NK/T-cell lymphoma (nodal T/NK-cell lymphoma of nasal type) in comparison with nasal NK/T-cell lymphoma with secondary lymph node involvement (n = 24) and peripheral T-cell lymphoma (PTCL) of cytotoxic molecule (CTM)+ and EBV+ type (n = 21).
|
18370955 |
2008 |
Lymphoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Expression of CD56 is associated with a poor prognosis in subcutaneous panniculitis-like T-cell lymphoma and blastic natural killer cell lymphoma.
|
17052504 |
2006 |
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Fifty-one cases of cCD3+ T-cell intracellular antigen (TIA-1)+ CD56+ lymphomas of extranodal/extranasal origin were included in the study.
|
15139996 |
2004 |
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
To describe the clinical, pathological and molecular features in six cases of CD56+ lymphoma with cutaneous presentation.
|
12653743 |
2003 |
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Among these six cases, four female CD56(-)/CD44(-)/CD8(-)/CD45RO(+)/CD45RA(-) cases constituted a distinct group with a better prognosis than the rest of the male cases of sinonasal lymphomas.
|
12533686 |
2003 |
Lymphoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
We report the clinical and laboratory findings of a patient with an aggressive Epstein-Barr virus positive CD2+/CD56+ natural killer-cell lymphoma with a high mitotic activity and complex chromosomal abnormalities presenting with life-threatening pericardial and pleural effusions, disseminated skin lesions, breast nodule and large suprarenal masses.
|
11911423 |
2002 |
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
We report 4 cases of lymphomas/leukemias with the unusual CD56/CD4 phenotype.
|
11488062 |
2001 |
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Agranular CD4+CD56+ blastic natural killer leukemia/lymphoma.
|
11401089 |
2001 |
Lymphoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
A rare form of putative natural killer (NK) cell lymphoma called blastic NK cell lymphoma appears to be clinicopathologically distinctive in showing a homogenous lymphoblast, variable expression of CD2, CD4, CD56 and TdT, negative for surface CD3, T-cell receptor antigen, CD16, CD34 and lack of association with Epstein-Barr virus (EBV).
|
11328295 |
2001 |
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Coexistence of two distinct cell populations (CD56(+)TcRgammadelta(+) and CD56(+)TcRgammadelta(-)) in a case of aggressive CD56(+) lymphoma/leukemia.
|
10800166 |
2000 |
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Four patients with cutaneous CD4+ and CD56+ lymphoma were studied.
|
10828627 |
2000 |
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
Thus, there seems to be a useful distinction between the classical NK/T type of nasal lymphoma (CD56+/n-cdk6+/CD44-/TcR-GR-) and PTL (CD56-/n-cdk6-/CD44+/TcR-GR+) involving the nasal region.
|
10879740 |
2000 |
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
The indolent behavior of this tumor indicates its similarity to other primary cutaneous CD30+ large cell lymphomas and its difference from other CD56+ lymphomas involving the skin, which often exhibit an aggressive clinical course.
|
11048978 |
2000 |
Lymphoma
|
0.100 |
Biomarker
|
group |
BEFREE |
When immunostained using paraffin embedded tissue, 6 upper aerodigestive lymphomas were negative for CD56 in which 4 cases lacked clonal TCR gene rearrangement.
|
11066052 |
2000 |
Lymphoma
|
0.100 |
AlteredExpression
|
group |
BEFREE |
Seven retrospectively identified cases of lymphomas with co-expression of CD56 and CD30 presenting in the skin comprise this study.
|
10955685 |
2000 |